Prognostic significance of programmed cell death 1 expression on CD8+T cells in various cancers: a systematic review and meta-analysis
Increased PD-1 expression on CD8+ T cells is considered as a hallmark for T-cell exhaustion, and is thought to be related to the prognosis of cancer patients. However, discrepant results have made it difficult to apply PD-1+CD8+T cells and tumor prognosis to clinical practice. Therefore, we conducte...
Saved in:
Published in | Frontiers in oncology Vol. 14; p. 1531219 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
14.01.2025
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Increased PD-1 expression on CD8+ T cells is considered as a hallmark for T-cell exhaustion, and is thought to be related to the prognosis of cancer patients. However, discrepant results have made it difficult to apply PD-1+CD8+T cells and tumor prognosis to clinical practice. Therefore, we conducted a meta-analysis to evaluate its prognostic value in human cancers.
PRISMA reporting guidelines were strictly followed for conducting the current meta-analysis. The PubMed, Web of Science, Embase databases were searched from inception to November 2024. The pooled Hazard Ratio (HR) along with 95% confidence intervals (CIs) of each article were combined for the associations of PD-1+CD8+ T cells with overall survival (OS), progression- free survival (PFS) and disease-free survival(DFS). Subgroup analyses were performed for area, specimen type, cancer type, treatment, detected method and cancer stage.
A total of 20 studies (23 cohorts, 3086 cancer patients) were included in our study. The expression PD-1+CD8+ T cells in cancer patients tended to predict poor overall survival (OS) (HR: 1.379, 95%CI: 1.084-1.753,
= 0.009), and unfavorable disease-free survival(DFS) (HR: 1.468, 95%CI: 0.931-2.316,
=0.099), though it did not reach statistical significance. Begg's and Egger's test demonstrated that no obvious publication bias was exist.
High PD-1 expression on CD8+ T cells is associated with worse survival outcomes, which can be potentially used as a prognostic marker of malignant tumor. |
---|---|
AbstractList | Increased PD-1 expression on CD8+ T cells is considered as a hallmark for T-cell exhaustion, and is thought to be related to the prognosis of cancer patients. However, discrepant results have made it difficult to apply PD-1+CD8+T cells and tumor prognosis to clinical practice. Therefore, we conducted a meta-analysis to evaluate its prognostic value in human cancers.BackgroundIncreased PD-1 expression on CD8+ T cells is considered as a hallmark for T-cell exhaustion, and is thought to be related to the prognosis of cancer patients. However, discrepant results have made it difficult to apply PD-1+CD8+T cells and tumor prognosis to clinical practice. Therefore, we conducted a meta-analysis to evaluate its prognostic value in human cancers.PRISMA reporting guidelines were strictly followed for conducting the current meta-analysis. The PubMed, Web of Science, Embase databases were searched from inception to November 2024. The pooled Hazard Ratio (HR) along with 95% confidence intervals (CIs) of each article were combined for the associations of PD-1+CD8+ T cells with overall survival (OS), progression- free survival (PFS) and disease-free survival(DFS). Subgroup analyses were performed for area, specimen type, cancer type, treatment, detected method and cancer stage.MethodsPRISMA reporting guidelines were strictly followed for conducting the current meta-analysis. The PubMed, Web of Science, Embase databases were searched from inception to November 2024. The pooled Hazard Ratio (HR) along with 95% confidence intervals (CIs) of each article were combined for the associations of PD-1+CD8+ T cells with overall survival (OS), progression- free survival (PFS) and disease-free survival(DFS). Subgroup analyses were performed for area, specimen type, cancer type, treatment, detected method and cancer stage.A total of 20 studies (23 cohorts, 3086 cancer patients) were included in our study. The expression PD-1+CD8+ T cells in cancer patients tended to predict poor overall survival (OS) (HR: 1.379, 95%CI: 1.084-1.753, p= 0.009), and unfavorable disease-free survival(DFS) (HR: 1.468, 95%CI: 0.931-2.316, p=0.099), though it did not reach statistical significance. Begg's and Egger's test demonstrated that no obvious publication bias was exist.ResultsA total of 20 studies (23 cohorts, 3086 cancer patients) were included in our study. The expression PD-1+CD8+ T cells in cancer patients tended to predict poor overall survival (OS) (HR: 1.379, 95%CI: 1.084-1.753, p= 0.009), and unfavorable disease-free survival(DFS) (HR: 1.468, 95%CI: 0.931-2.316, p=0.099), though it did not reach statistical significance. Begg's and Egger's test demonstrated that no obvious publication bias was exist.High PD-1 expression on CD8+ T cells is associated with worse survival outcomes, which can be potentially used as a prognostic marker of malignant tumor.ConclusionsHigh PD-1 expression on CD8+ T cells is associated with worse survival outcomes, which can be potentially used as a prognostic marker of malignant tumor. BackgroundIncreased PD-1 expression on CD8+ T cells is considered as a hallmark for T-cell exhaustion, and is thought to be related to the prognosis of cancer patients. However, discrepant results have made it difficult to apply PD-1+CD8+T cells and tumor prognosis to clinical practice. Therefore, we conducted a meta-analysis to evaluate its prognostic value in human cancers.MethodsPRISMA reporting guidelines were strictly followed for conducting the current meta-analysis. The PubMed, Web of Science, Embase databases were searched from inception to November 2024. The pooled Hazard Ratio (HR) along with 95% confidence intervals (CIs) of each article were combined for the associations of PD-1+CD8+ T cells with overall survival (OS), progression- free survival (PFS) and disease-free survival(DFS). Subgroup analyses were performed for area, specimen type, cancer type, treatment, detected method and cancer stage.ResultsA total of 20 studies (23 cohorts, 3086 cancer patients) were included in our study. The expression PD-1+CD8+ T cells in cancer patients tended to predict poor overall survival (OS) (HR: 1.379, 95%CI: 1.084-1.753, p= 0.009), and unfavorable disease-free survival(DFS) (HR: 1.468, 95%CI: 0.931-2.316, p=0.099), though it did not reach statistical significance. Begg’s and Egger’s test demonstrated that no obvious publication bias was exist.ConclusionsHigh PD-1 expression on CD8+ T cells is associated with worse survival outcomes, which can be potentially used as a prognostic marker of malignant tumor. Increased PD-1 expression on CD8+ T cells is considered as a hallmark for T-cell exhaustion, and is thought to be related to the prognosis of cancer patients. However, discrepant results have made it difficult to apply PD-1+CD8+T cells and tumor prognosis to clinical practice. Therefore, we conducted a meta-analysis to evaluate its prognostic value in human cancers. PRISMA reporting guidelines were strictly followed for conducting the current meta-analysis. The PubMed, Web of Science, Embase databases were searched from inception to November 2024. The pooled Hazard Ratio (HR) along with 95% confidence intervals (CIs) of each article were combined for the associations of PD-1+CD8+ T cells with overall survival (OS), progression- free survival (PFS) and disease-free survival(DFS). Subgroup analyses were performed for area, specimen type, cancer type, treatment, detected method and cancer stage. A total of 20 studies (23 cohorts, 3086 cancer patients) were included in our study. The expression PD-1+CD8+ T cells in cancer patients tended to predict poor overall survival (OS) (HR: 1.379, 95%CI: 1.084-1.753, = 0.009), and unfavorable disease-free survival(DFS) (HR: 1.468, 95%CI: 0.931-2.316, =0.099), though it did not reach statistical significance. Begg's and Egger's test demonstrated that no obvious publication bias was exist. High PD-1 expression on CD8+ T cells is associated with worse survival outcomes, which can be potentially used as a prognostic marker of malignant tumor. |
Author | Cui, Meng Wan, Zhiyong Yang, Jia Li, Fanmin Chen, Junliang Liao, Dan Cui, Zhiwei Yang, Yang Xiang, Yin |
AuthorAffiliation | 1 Department of General Practice, People’s Hospital of Leshan , Leshan , China 2 Department of Medical Laboratory, People’s Hospital of Leshan , Leshan , China |
AuthorAffiliation_xml | – name: 1 Department of General Practice, People’s Hospital of Leshan , Leshan , China – name: 2 Department of Medical Laboratory, People’s Hospital of Leshan , Leshan , China |
Author_xml | – sequence: 1 givenname: Zhiyong surname: Wan fullname: Wan, Zhiyong – sequence: 2 givenname: Meng surname: Cui fullname: Cui, Meng – sequence: 3 givenname: Jia surname: Yang fullname: Yang, Jia – sequence: 4 givenname: Dan surname: Liao fullname: Liao, Dan – sequence: 5 givenname: Junliang surname: Chen fullname: Chen, Junliang – sequence: 6 givenname: Fanmin surname: Li fullname: Li, Fanmin – sequence: 7 givenname: Yin surname: Xiang fullname: Xiang, Yin – sequence: 8 givenname: Zhiwei surname: Cui fullname: Cui, Zhiwei – sequence: 9 givenname: Yang surname: Yang fullname: Yang, Yang |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39876901$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkt1q3DAQhU1JadI0D9CbostC8VZ_tuXelLLpTyDQXqTQOzGWRhsFW9pK3m33BfLctXe3IRECDZrDd8TovCxOQgxYFK8ZXQih2vcuBrPglMsFqwTjrH1WnHEuZNlK8evkUX1aXOR8R6dVV5RR8aI4Fa1q6pays-L-R4qrEPPoDcl-FbzzBoJBEh1ZT60Ew4CWGOx7YhHGW8II_l0nzNnHQKa9vFTvbvaCTHwgW0g-bjLZU1L-QIDkXR5xgNki4dbjHwLBkgFHKCFAv8s-vyqeO-gzXhzP8-Lnl883y2_l9fevV8tP16WRTI2lxMrYWkJXd1UnhHEgpROmEhIM64TpWovcWmNczeuGW-UUqxUXjVNcWobivLg6cG2EO71OfoC00xG83l_EtNKQpof2qCvOuLIgOodcKmwVZd3kx0QHLUXnJtbHA2u96aYZGQxjgv4J9Gkn-Fu9ilvNWNNwTquJ8PZISPH3BvOoB5_nSULAaYZasJq2oq2rWfrmsdmDy_-fnATsIDAp5pzQPUgY1XNg9BwYPQdGHwMj_gH6l7b3 |
Cites_doi | 10.1136/jitc-2019-000422 10.1182/blood-2008-12-195792 10.1158/0008-5472.CAN-16-3167 10.1007/s00262-018-2138-8 10.21873/anticanres.13132 10.1136/jitc-2023-007585 10.1186/s40880-017-0226-3 10.1186/s40425-019-0499-y 10.1158/1078-0432.CCR-19-3003 10.1038/modpathol.2010.130 10.1158/1078-0432.CCR-17-2156 10.1016/j.radonc.2015.07.003 10.1038/s41467-018-06653-9 10.1007/s10120-023-01364-7 10.1056/NEJMoa1606774 10.1146/annurev.immunol.26.021607.090331 10.1038/s41591-018-0057-z 10.18632/oncotarget.5583 10.1038/s41598-017-08479-9 10.1073/pnas.1705327114 10.3390/biomedicines10112794 10.1038/nature10673 10.1177/1758835919853193 10.1186/s40425-019-0814-7 10.1016/j.lungcan.2018.11.038 10.1016/j.cellimm.2017.01.001 10.1056/NEJMoa1809615 10.1016/j.it.2013.10.001 10.1007/s10654-010-9491-z 10.1080/2162402X.2015.1062969 10.3390/cancers15153955 10.1111/cas.12502 10.1038/nature05115 10.1016/j.coi.2014.01.004 10.3389/fonc.2022.837560 10.1042/CS20191261 10.1172/JCI46102 10.1038/s41590-020-0769-3 10.3390/cancers15051389 10.1126/science.1203486 10.1002/ijc.25397 10.1038/s41416-022-01939-8 10.1056/NEJMoa1801005 10.1177/00045632231184716 10.1158/2326-6066.CIR-15-0097 |
ContentType | Journal Article |
Copyright | Copyright © 2025 Wan, Cui, Yang, Liao, Chen, Li, Xiang, Cui and Yang. Copyright © 2025 Wan, Cui, Yang, Liao, Chen, Li, Xiang, Cui and Yang 2025 Wan, Cui, Yang, Liao, Chen, Li, Xiang, Cui and Yang |
Copyright_xml | – notice: Copyright © 2025 Wan, Cui, Yang, Liao, Chen, Li, Xiang, Cui and Yang. – notice: Copyright © 2025 Wan, Cui, Yang, Liao, Chen, Li, Xiang, Cui and Yang 2025 Wan, Cui, Yang, Liao, Chen, Li, Xiang, Cui and Yang |
DBID | AAYXX CITATION NPM 7X8 5PM DOA |
DOI | 10.3389/fonc.2024.1531219 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2234-943X |
ExternalDocumentID | oai_doaj_org_article_52128da3bfe248e9801bfa413ba90eff PMC11772205 39876901 10_3389_fonc_2024_1531219 |
Genre | Journal Article Review |
GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EBS EJD EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E OK1 PGMZT RNS RPM IAO IEA IHR IHW IPNFZ NPM RIG 7X8 5PM |
ID | FETCH-LOGICAL-c418t-4e5cd64ab6b5b33cfa44f3c534ac1b3cb9de2ddccf62672d8f8168237f824d1e3 |
IEDL.DBID | M48 |
ISSN | 2234-943X |
IngestDate | Wed Aug 27 01:18:39 EDT 2025 Thu Aug 21 18:40:30 EDT 2025 Fri Jul 11 11:00:15 EDT 2025 Fri Jan 31 01:44:33 EST 2025 Tue Jul 01 01:56:10 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | overall survival cancer PD-1+CD8+ T cells disease-free survival progression-free survival |
Language | English |
License | Copyright © 2025 Wan, Cui, Yang, Liao, Chen, Li, Xiang, Cui and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c418t-4e5cd64ab6b5b33cfa44f3c534ac1b3cb9de2ddccf62672d8f8168237f824d1e3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 Edited by: Yu’e Liu, Boston Children’s Hospital and Harvard Medical School, United States Reviewed by: Jin-Ming Zhang, University of Texas Health Science Center at Houston, United States These authors have contributed equally to this work Xutong Xue, Boston Children’s Hospital and Harvard Medical School, United States |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fonc.2024.1531219 |
PMID | 39876901 |
PQID | 3160939655 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_52128da3bfe248e9801bfa413ba90eff pubmedcentral_primary_oai_pubmedcentral_nih_gov_11772205 proquest_miscellaneous_3160939655 pubmed_primary_39876901 crossref_primary_10_3389_fonc_2024_1531219 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2025-01-14 |
PublicationDateYYYYMMDD | 2025-01-14 |
PublicationDate_xml | – month: 01 year: 2025 text: 2025-01-14 day: 14 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland |
PublicationTitle | Frontiers in oncology |
PublicationTitleAlternate | Front Oncol |
PublicationYear | 2025 |
Publisher | Frontiers Media S.A |
Publisher_xml | – name: Frontiers Media S.A |
References | Kansy (B23) 2017; 77 Thommen (B8) 2015; 3 Lu (B35) 2017; 313 Baitsch (B5) 2011; 121 Mazzaschi (B20) 2018; 24 Homicsko (B31) 2023; 11 Mellman (B2) 2011; 480 Schreiner (B9) 2016; 5 Choo (B17) 2023; 26 Schmid (B41) 2018; 379 Kamphorst (B43) 2017; 114 Gao (B28) 2017; 36 Ahmadzadeh (B11) 2009; 114 Keir (B6) 2008; 26 Schietinger (B4) 2014; 35 Zhu (B42) 2022; 12 Pokryvkova (B14) 2022; 10 Thommen (B16) 2018; 24 Waki (B22) 2014; 105 Saito (B21) 2019; 39 Yang (B32) 2023; 15 Shen (B29) 2017; 7 Yu (B19) 2022; 127 Tang (B25) 2020; 26 Kumagai (B44) 2020; 21 Day (B7) 2006; 443 Guo (B27) 2020; 134 Kotsakis (B33) 2019; 11 Egelston (B39) 2018; 9 Varki (B34) 2018; 67 Mittal (B1) 2014; 27 Stang (B15) 2010; 25 Shen (B37) 2020; 8 Qin (B38) 2015; 6 Shin (B18) 2023; 15 Lim (B36) 2015; 117 Reck (B40) 2016; 375 Gandhi (B45) 2018; 378 Hsu (B12) 2010; 23 Mazzaschi (B26) 2019; 127 You (B24) 2024; 61 Yeong (B30) 2019; 7 Schreiber (B3) 2011; 331 Shi (B10) 2011; 128 Ma (B13) 2019; 7 |
References_xml | – volume: 8 year: 2020 ident: B37 article-title: Pd-1 does not mark tumor-infiltrating Cd8+ T cell dysfunction in human gastric cancer publication-title: J immunotherapy Cancer doi: 10.1136/jitc-2019-000422 – volume: 114 year: 2009 ident: B11 article-title: Tumor antigen-specific Cd8 T cells infiltrating the tumor express high levels of Pd-1 and are functionally impaired publication-title: Blood doi: 10.1182/blood-2008-12-195792 – volume: 77 year: 2017 ident: B23 article-title: Pd-1 status in Cd8(+) T cells associates with survival and anti-Pd-1 therapeutic outcomes in head and neck cancer publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-16-3167 – volume: 67 year: 2018 ident: B34 article-title: Pd-L1, B7-H3, and Pd-1 expression in immunocompetent vs. Immunosuppressed patients with cutaneous squamous cell carcinoma publication-title: Cancer immunology immunotherapy: CII doi: 10.1007/s00262-018-2138-8 – volume: 39 year: 2019 ident: B21 article-title: Pd-1 expression on circulating Cd8(+) T-cells as a prognostic marker for patients with gastric cancer publication-title: Anticancer Res doi: 10.21873/anticanres.13132 – volume: 11 year: 2023 ident: B31 article-title: Pd-1-expressing macrophages and Cd8 T cells are independent predictors of clinical benefit from Pd-1 inhibition in advanced mesothelioma publication-title: J immunotherapy Cancer doi: 10.1136/jitc-2023-007585 – volume: 36 start-page: 61 year: 2017 ident: B28 article-title: Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and Cd8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4n+M0 gastric adenocarcinoma publication-title: Chin J Cancer doi: 10.1186/s40880-017-0226-3 – volume: 7 start-page: 34 year: 2019 ident: B30 article-title: Prognostic value of Cd8 + Pd-1+ Immune infiltrates and Pdcd1 gene expression in triple negative breast cancer publication-title: J immunotherapy Cancer doi: 10.1186/s40425-019-0499-y – volume: 26 year: 2020 ident: B25 article-title: Characterization of immune dysfunction and identification of prognostic immune-related risk factors in acute myeloid leukemia publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-19-3003 – volume: 23 year: 2010 ident: B12 article-title: Increase of programmed death-1-expressing intratumoral Cd8 T cells predicts a poor prognosis for nasopharyngeal carcinoma publication-title: Modern Pathol doi: 10.1038/modpathol.2010.130 – volume: 24 year: 2018 ident: B20 article-title: Low Pd-1 expression in cytotoxic Cd8(+) tumor-infiltrating lymphocytes confers an immune-privileged tissue microenvironment in Nsclc with a prognostic and predictive value publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-2156 – volume: 117 year: 2015 ident: B36 article-title: High ratio of programmed cell death protein 1 (Pd-1)(+)/Cd8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy publication-title: Radiotherapy Oncol doi: 10.1016/j.radonc.2015.07.003 – volume: 9 start-page: 4297 year: 2018 ident: B39 article-title: Human breast tumor-infiltrating Cd8(+) T cells retain polyfunctionality despite Pd-1 expression publication-title: Nat Commun doi: 10.1038/s41467-018-06653-9 – volume: 26 start-page: 393 year: 2023 ident: B17 article-title: Clinical relevance of Pd-1 positive Cd8 T-cells in gastric cancer publication-title: Gastric Cancer doi: 10.1007/s10120-023-01364-7 – volume: 375 year: 2016 ident: B40 article-title: Pembrolizumab versus chemotherapy for Pd-L1-positive non-small-cell lung cancer publication-title: New Engl J Med doi: 10.1056/NEJMoa1606774 – volume: 26 start-page: 677 year: 2008 ident: B6 article-title: Pd-1 and its ligands in tolerance and immunity publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.26.021607.090331 – volume: 24 start-page: 994 year: 2018 ident: B16 article-title: A transcriptionally and functionally distinct Pd-1(+) Cd8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with Pd-1 blockade publication-title: Nat Med doi: 10.1038/s41591-018-0057-z – volume: 6 year: 2015 ident: B38 article-title: High Pd-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer publication-title: Oncotarget doi: 10.18632/oncotarget.5583 – volume: 7 start-page: 7848 year: 2017 ident: B29 article-title: Prognostic value of programmed cell death protein 1 expression on Cd8+ T lymphocytes in pancreatic cancer publication-title: Sci Rep doi: 10.1038/s41598-017-08479-9 – volume: 114 year: 2017 ident: B43 article-title: Proliferation of Pd-1+ Cd8 T cells in peripheral blood after Pd-1-targeted therapy in lung cancer patients publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1705327114 – volume: 10 year: 2022 ident: B14 article-title: Pd1(+)Cd8(+) cells are an independent prognostic marker in patients with head and neck cancer publication-title: Biomedicines doi: 10.3390/biomedicines10112794 – volume: 480 year: 2011 ident: B2 article-title: Cancer immunotherapy comes of age publication-title: Nature doi: 10.1038/nature10673 – volume: 11 year: 2019 ident: B33 article-title: Cd8(+) Pd-1(+) T-cells and Pd-L1(+) circulating tumor cells in chemotherapy-naive non-small cell lung cancer: towards their clinical relevance publication-title: Ther Adv Med Oncol doi: 10.1177/1758835919853193 – volume: 7 start-page: 331 year: 2019 ident: B13 article-title: Pd1(Hi) Cd8(+) T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma publication-title: J immunotherapy Cancer doi: 10.1186/s40425-019-0814-7 – volume: 127 year: 2019 ident: B26 article-title: The circulating pool of functionally competent Nk and Cd8+ Cells predicts the outcome of anti-Pd1 treatment in advanced Nsclc publication-title: Lung Cancer doi: 10.1016/j.lungcan.2018.11.038 – volume: 313 start-page: 43 year: 2017 ident: B35 article-title: Tumor antigen-specific Cd8(+) T cells are negatively regulated by Pd-1 and Tim-3 in human gastric cancer publication-title: Cell Immunol doi: 10.1016/j.cellimm.2017.01.001 – volume: 379 year: 2018 ident: B41 article-title: Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer publication-title: New Engl J Med doi: 10.1056/NEJMoa1809615 – volume: 35 start-page: 51 year: 2014 ident: B4 article-title: Tolerance and exhaustion: defining mechanisms of T cell dysfunction publication-title: Trends Immunol doi: 10.1016/j.it.2013.10.001 – volume: 25 year: 2010 ident: B15 article-title: Critical evaluation of the newcastle-ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses publication-title: Eur J Epidemiol doi: 10.1007/s10654-010-9491-z – volume: 5 start-page: e1062969 year: 2016 ident: B9 article-title: Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor publication-title: Oncoimmunology doi: 10.1080/2162402X.2015.1062969 – volume: 15 year: 2023 ident: B18 article-title: Early increase in circulating Pd-1(+)Cd8(+) T cells predicts favorable survival in patients with advanced gastric cancer receiving chemotherapy publication-title: Cancers doi: 10.3390/cancers15153955 – volume: 105 year: 2014 ident: B22 article-title: Pd-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer publication-title: Cancer Sci doi: 10.1111/cas.12502 – volume: 443 year: 2006 ident: B7 article-title: Pd-1 expression on Hiv-specific T cells is associated with T-cell exhaustion and disease progression publication-title: Nature doi: 10.1038/nature05115 – volume: 27 start-page: 16 year: 2014 ident: B1 article-title: New insights into cancer immunoediting and its three component phases–elimination, equilibrium and escape publication-title: Curr Opin Immunol doi: 10.1016/j.coi.2014.01.004 – volume: 12 year: 2022 ident: B42 article-title: Restored Cd8(+)Pd-1(+) T cells facilitate the response to anti-Pd-1 for patients with pancreatic ductal adenocarcinoma publication-title: Front Oncol doi: 10.3389/fonc.2022.837560 – volume: 134 year: 2020 ident: B27 article-title: Tumoral Pd-1hicd8+ T cells are partially exhausted and predict favorable outcome in triple-negative breast cancer publication-title: Clin Sci doi: 10.1042/CS20191261 – volume: 121 year: 2011 ident: B5 article-title: Exhaustion of tumor-specific Cd8(+) T cells in metastases from melanoma patients publication-title: J Clin Invest doi: 10.1172/JCI46102 – volume: 21 year: 2020 ident: B44 article-title: The Pd-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of Pd-1 blockade therapies publication-title: Nat Immunol doi: 10.1038/s41590-020-0769-3 – volume: 15 year: 2023 ident: B32 article-title: Pd-1(+)Cd8(+) T cells proximal to Pd-L1(+)Cd68(+) macrophages are associated with poor prognosis in pancreatic ductal adenocarcinoma patients publication-title: Cancers doi: 10.3390/cancers15051389 – volume: 331 year: 2011 ident: B3 article-title: Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion publication-title: Science doi: 10.1126/science.1203486 – volume: 128 year: 2011 ident: B10 article-title: Pd-1 and Pd-L1 upregulation promotes Cd8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients publication-title: Int J Cancer doi: 10.1002/ijc.25397 – volume: 127 year: 2022 ident: B19 article-title: Intratumoral Pd-1(+)Cd8(+) T cells associate poor clinical outcomes and adjuvant chemotherapeutic benefit in gastric cancer publication-title: Br J Cancer doi: 10.1038/s41416-022-01939-8 – volume: 378 year: 2018 ident: B45 article-title: Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer publication-title: New Engl J Med doi: 10.1056/NEJMoa1801005 – volume: 61 start-page: 79 year: 2024 ident: B24 article-title: Increased Pd-1 expression of bone marrow T-cells in acute myeloid leukaemia patients after stem cell transplantation, and its association with overall survival publication-title: Ann Clin Biochem doi: 10.1177/00045632231184716 – volume: 3 year: 2015 ident: B8 article-title: Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-15-0097 |
SSID | ssj0000650103 |
Score | 2.3781142 |
SecondaryResourceType | review_article |
Snippet | Increased PD-1 expression on CD8+ T cells is considered as a hallmark for T-cell exhaustion, and is thought to be related to the prognosis of cancer patients.... BackgroundIncreased PD-1 expression on CD8+ T cells is considered as a hallmark for T-cell exhaustion, and is thought to be related to the prognosis of cancer... |
SourceID | doaj pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 1531219 |
SubjectTerms | cancer disease-free survival Oncology overall survival PD-1+CD8+ T cells progression-free survival |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LixQxEA6yB_Eivm1flOBJiTt5Tsebri6LsOJhF_YW8sQ9mJaZWfEX-Lut6u5dZ0TwIvSpO6RDfZVKVVL5irEX0WqzVCVyo6viOsrMwyJK7sh9Fuhw10xbA8ef7NGp_nhmzrZKfVFO2EQPPAlun-6W9jmoWIvUfXFoUWMNaHpjcItSK1lfXPO2gqnJBhsqYDAdY2IU5vbr0IixUOrXOMeFJGadrYVo5Ov_m5P5Z67k1uJzeIvdnL1GeDuN9ja7Vtoddv14Phe_y35-Xg2UMYefgTIyKP-H4IShwpyBhZ0D7dJDJqcPBJQfcw5sA3wO3vevTsYGazhv8B1D6OFiDWMvq_UbCPCb8xmm-y4QWoavZRN4mJlN7rHTww8nB0d8rrDAkxb9hutiUrY6RBtNVCqhYBGyZJQOSUSVostF5pxSxbhnKXNfqUyHVMvaS51FUffZXhtaechAhaySEBU9kiXZBVeSstmWPutsZSode3kpbv9tItLwGIAQNp6w8YSNn7Hp2DsC5KohcWCPL1Az_KwZ_l-a0bHnl3B6nDMkwdAKys4rYRdOOWtMxx5M8F79SjlcH9BJ6li_A_zOWHa_tPMvIy83nX_TveVH_2P0j9kNSaWGF4IL_YTtbVYX5Sn6P5v4bFT1X30cBtk priority: 102 providerName: Directory of Open Access Journals |
Title | Prognostic significance of programmed cell death 1 expression on CD8+T cells in various cancers: a systematic review and meta-analysis |
URI | https://www.ncbi.nlm.nih.gov/pubmed/39876901 https://www.proquest.com/docview/3160939655 https://pubmed.ncbi.nlm.nih.gov/PMC11772205 https://doaj.org/article/52128da3bfe248e9801bfa413ba90eff |
Volume | 14 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqIiEuqLxToDISJ1DK-pmkEkJQKBXSIg5daW-Rn1CpdSC7ReUP9Hczk3gLi_aEFOUQ23n4y3i-scczhDy3WqpKBFsqGUUpLfelmVheNkifGRDu6HFqYPpZH8_kp7mab5FVeqvcgYuNph3mk5r1Z_uXP369AYF_jRYn6NtXsUsYjJDLfRBfxjEI6A1QTBXK6TSz_XFgVpjVYFzb3NxyTTsNQfw3Mc9_HSj_0khHO-R2ppL07Yj9HbIV0l1yc5oXy--Rqy99h250UEzRTQOdghBj2kWa3bLg5hSn7qlHJkgZDZfZMTZROA7f1y9PhgoLeproT7Cru4sFHe7SLw6ooX8CQdNxEww1ydPzsDSlyeFO7pPZ0YeTw-Myp10onWT1spRBOa-lsdoqK4SLRgKOTglpHLPC2cYH7r1zEYyhivs6Yu4OLqpYc-lZEA_IdupSeESoMF44xiLQlAoHiyY4ob0OtZdecxcK8mLV3e33MbpGC1YJYtMiNi1i02ZsCvIOAbmuiIGxhwtd_7XNctbiVuTaG2Fj4LIODShgCx_AhDXNJMRYkGcrOFsQJOxBkwL0XSuYnjSi0UoV5OEI7_WjRANKA5hTQeo14NfeZb0knX4bgnXjojhuZt79_6aPyS2OWYcnrGTyCdle9hfhKVChpd0bphDg_HHO9oaf_TdZBA7a |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+significance+of+programmed+cell+death+1+expression+on+CD8%2BT+cells+in+various+cancers%3A+a+systematic+review+and+meta-analysis&rft.jtitle=Frontiers+in+oncology&rft.au=Wan%2C+Zhiyong&rft.au=Cui%2C+Meng&rft.au=Yang%2C+Jia&rft.au=Liao%2C+Dan&rft.date=2025-01-14&rft.pub=Frontiers+Media+S.A&rft.eissn=2234-943X&rft.volume=14&rft_id=info:doi/10.3389%2Ffonc.2024.1531219&rft.externalDocID=PMC11772205 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2234-943X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2234-943X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2234-943X&client=summon |